KR20000057242A - 의약 조성물 - Google Patents
의약 조성물 Download PDFInfo
- Publication number
- KR20000057242A KR20000057242A KR1019990704614A KR19997004614A KR20000057242A KR 20000057242 A KR20000057242 A KR 20000057242A KR 1019990704614 A KR1019990704614 A KR 1019990704614A KR 19997004614 A KR19997004614 A KR 19997004614A KR 20000057242 A KR20000057242 A KR 20000057242A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- hydrogen atom
- hydroxy
- independently
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
조성물 | Cmax | AUC0-8hr(ng·hr/㎖) | ||
평균 | CV(%) | 평균 | CV(%) | |
실시예3(19) | 5.1 | 30 | 14.9 | 20 |
대조조성물 | 〈 3.0 | 〉 50 | 〈 5.0 | 〉 50 |
Claims (7)
- 난수용성 약물, 계면활성제 및 고형기제를 함유하는 의약 조성물.
- 제 1 항에 있어서, 고형기제가 고형중합체인 의약 조성물.
- 제 2 항에 있어서, 고체분산체인 의약 조성물.
- 제 1 항에 있어서, 난수용성 약물이, 하기 화학식 I을 갖는 트리시클로화합물 또는 의약으로서 허용되는 그의 염인 의약 조성물:[화학식 I]식중, R1및 R2, R3및 R4, R5및 R6의 인접하는 각각의 쌍은, 각각 독립적으로,a) 2개의 인접하는 수소원자를 나타내거나, 또는b) 결합하고 있는 탄소원자와의 사이에서 또하나의 결합을 형성할 수 있고, 더욱이 R2는 알킬기일 수 있으며,R7은 수소원자, 히드록시기, 보호된 히드록시기, 또는 알킬옥시기를 나타내거나, 또는 R1과 같이 되어 옥소기를 나타낼 수 있으며,R8및 R9는 독립적으로 수소원자, 히드록시기를,R10은 수소원자, 알킬기, 1 이상의 히드록시기에 의해 치환된 알킬기, 알케닐기, 1 이상의 히드록시기에 의해 치환된 알케닐기, 또는 옥소기에 의해 치환된 알킬기를,X는 옥소기, (수소원자, 히드록시기), (수소원자, 수소원자), 또는 식 -CH2O-로 표시되는 기를,Y는 옥소기, (수소원자, 히드록시기), (수소원자, 수소원자), 또는 식 N-NR11R12또는 N-OR13으로 표시되는 기를,R11및 R12는 독립적으로 수소원자, 알킬기, 아릴기 또는 토실기를,R13, R14, R15, R16, R17, R18, R19, R22및 R23은 독립적으로 수소원자 또는 알킬기를,R20및 R21은 독립적으로 옥소기, 또는 각각 독립적으로 (R20a, 수소원자) 및 (R21a, 수소원자)이어도 좋고, R20a 및 R21a는 독립적으로 히드록시기, 알킬옥시기, 또는, 식 OCH2OCH2CH2OCH3로 표시되는 기, 또는R21a는 보호된 히드록시기를 나타내고, 또한 R20a 및 R21a는 함께 되어 에폭시드환중의 산소원자를 나타낼 수 있으며,n은 1 또는 2을 나타내고,상기의 의미에 덧붙여, 또한 Y, R10및 R23은 그들이 결합하고 있는 탄소원자와 다같이 포화 또는 불포화의 5원 또는 6원환으로 이루어지는 질소원자, 황원자 및/또는 산소원자를 함유하는 복소환기를 나타낼 수 있으나, 그 복소환기는 알킬기, 히드록시기, 1 이상의 히드록시기에 의해 치환된 알킬기, 알킬옥시기, 벤질기 및 식 -CH2Se(C6H5)로 표시되는 기에서 선택되는 1 이상의 기에 의해 치환될 수 있다.
- 제 4 항에 있어서, 트리시클로화합물(Ⅰ)이, R3및 R4, R5및 R6의 인접하는 각각의 쌍이 그들이 결합하는 탄소원자와의 사이에 형성된 또하나의 결합을 형성하고 있으며,R8과 R23은 독립적으로 수소원자,R9는 히드록시기,R10은 메틸, 에틸, 프로필 또는 알릴기,X는 (수소원자, 수소원자) 또는 옥소기,Y는 옥소기,R14, R15, R16, R17, R18, R19와 R22는 각각 메틸기,R20과 R21은 독립적으로 (R20a, 수소원자) 또는(R21a, 수소원자), (단, R20a와 R21a는 각각 히드록시기 또는 알콕시기, 또는 R21a는 보호된 히드록시기), 그리고n은 1 또는 2로 표시되는 화합물인 의약 조성물.
- 제 5 항에 있어서, 트리시클로화합물(Ⅰ)이 17-알릴-1,14-디히드록시-12-[2-(4-히드록시-3-메톡시시클로헥실)-1-메틸비닐]-23,25-디메톡시-13,19,21,27-테트라메틸-11,28-디옥사-4-아자트리시클로[22.3.1.04,9]옥타코스-18-엔-2,3,10,16-테트라온인 의약 조성물.
- 제 1 항에 있어서, 난수용성 약물 및 계면활성제를 용해시킨 유기용매에, 고형기제를 가하여 반죽하는 공정, 그리고 얻어진 혼합물로부터 유기용매를 제거하여, 건조, 분쇄하는 공정을 포함하는 의약 조성물의 제조방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP326618/1996 | 1996-12-06 | ||
JP32661896 | 1996-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20000057242A true KR20000057242A (ko) | 2000-09-15 |
Family
ID=18189823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990704614A KR20000057242A (ko) | 1996-12-06 | 1997-12-05 | 의약 조성물 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6346537B1 (ko) |
EP (1) | EP0943327B1 (ko) |
JP (1) | JP4284706B2 (ko) |
KR (1) | KR20000057242A (ko) |
CN (1) | CN1149979C (ko) |
AR (1) | AR008927A1 (ko) |
AT (1) | ATE367150T1 (ko) |
AU (1) | AU726451B2 (ko) |
BR (1) | BR9713866A (ko) |
CA (1) | CA2274485C (ko) |
DE (1) | DE69737936T2 (ko) |
ES (1) | ES2286835T3 (ko) |
HU (1) | HU228680B1 (ko) |
RU (1) | RU2197226C2 (ko) |
TW (1) | TW426516B (ko) |
WO (1) | WO1998024418A1 (ko) |
ZA (1) | ZA9710927B (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1064942T1 (en) | 1998-03-26 | 2004-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparation of a macrolide |
FR2781373B1 (fr) * | 1998-07-07 | 2001-09-21 | Pf Medicament | Formulations thixotropes pour le remplissage de gelules |
TR200102778T2 (tr) * | 1999-03-11 | 2002-05-21 | Fujisawa Pharmaceutical Co. Ltd. | Lipozom preparatları |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
AUPR529701A0 (en) * | 2001-05-28 | 2001-06-21 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
AR038681A1 (es) * | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
US20050147629A1 (en) * | 2002-06-28 | 2005-07-07 | Jutta Riedl | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
BRPI0412329A (pt) * | 2003-07-09 | 2006-09-05 | Chong Kun Dang Pharm Corp | dispersão sólida de tacrolimus e método de processar a mesma |
WO2005011635A2 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
CA2537041C (en) * | 2003-08-29 | 2012-04-03 | Lifecycle Pharma A/S | Modified release compositions comprising tacrolimus |
US8591946B2 (en) | 2003-08-29 | 2013-11-26 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
KR100866728B1 (ko) * | 2004-11-12 | 2008-11-03 | 주식회사종근당 | 타크로리무스를 함유하는 주사제 |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
US7652364B2 (en) * | 2005-12-21 | 2010-01-26 | Teradata Us, Inc. | Crossing conductive traces in a PCB |
GB0602632D0 (en) * | 2006-02-08 | 2006-03-22 | Pliva Istrazivacki Inst D O O | Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus |
EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
US9044391B2 (en) * | 2007-01-10 | 2015-06-02 | Board Of Regents, The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
KR100868295B1 (ko) * | 2007-02-15 | 2008-11-11 | 풍림무약주식회사 | 레플루노미드를 함유하는 고체분산체 및 이의 제조방법 |
CA2688381C (en) | 2007-05-30 | 2016-10-11 | Lifecycle Pharma A/S | Once daily oral dosage form comprising tacrolimus |
TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
US8222272B2 (en) * | 2008-04-11 | 2012-07-17 | Roxane Laboratories, Inc. | Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus) |
CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
WO2010005980A1 (en) * | 2008-07-08 | 2010-01-14 | Lifecycle Pharma A/S | Tacrolimus for improved treatment of transplant patients |
US20110201575A1 (en) * | 2008-09-17 | 2011-08-18 | Cj Cheiljedang Corporation | Stabilized solid dispersion of adefovir dipivoxil and preparation method thereof |
HUE028847T2 (en) | 2010-02-17 | 2017-01-30 | Veloxis Pharmaceuticals As | Stabilized tacrolimus preparation |
WO2011116034A1 (en) * | 2010-03-17 | 2011-09-22 | Lutran Industries, Inc. | Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication |
US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
US9168246B2 (en) | 2013-06-27 | 2015-10-27 | Veloxis Pharmaceutical A/S | Regimen for suppressing organ rejection |
CN105663092A (zh) * | 2016-03-03 | 2016-06-15 | 海南华益泰康药业有限公司 | 一种含有他克莫司固体分散体的缓释胶囊及其制备方法 |
CA3056766A1 (en) * | 2016-05-26 | 2017-11-30 | Dermala Inc. | Compositions and methods for treating acne vulgaris |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
AU635286B2 (en) | 1989-07-05 | 1993-03-18 | Astellas Pharma Inc. | Aqueous liquid composition for external use |
US5215995A (en) | 1989-10-16 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Hair revitalizing agent |
KR0177158B1 (ko) * | 1990-03-01 | 1999-03-20 | 후지사와 도모기찌로 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
IE65341B1 (en) | 1990-11-08 | 1995-10-18 | Fujisawa Pharmaceutical Co | Suspensions containing tricyclic compounds |
US5817333A (en) | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
AU5434094A (en) | 1992-11-18 | 1994-06-08 | Fujisawa Pharmaceutical Co., Ltd. | Prolonged-action pharmaceutical preparation |
JPH07291854A (ja) * | 1994-04-26 | 1995-11-07 | Tanabe Seiyaku Co Ltd | 溶解性の改善された医薬品製剤 |
FR2722984B1 (fr) * | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
-
1997
- 1997-12-04 TW TW086118225A patent/TW426516B/zh not_active IP Right Cessation
- 1997-12-04 ZA ZA9710927A patent/ZA9710927B/xx unknown
- 1997-12-05 CN CNB971816808A patent/CN1149979C/zh not_active Expired - Fee Related
- 1997-12-05 AT AT97946111T patent/ATE367150T1/de not_active IP Right Cessation
- 1997-12-05 WO PCT/JP1997/004452 patent/WO1998024418A1/ja active IP Right Grant
- 1997-12-05 JP JP52545598A patent/JP4284706B2/ja not_active Expired - Lifetime
- 1997-12-05 EP EP97946111A patent/EP0943327B1/en not_active Expired - Lifetime
- 1997-12-05 US US09/308,672 patent/US6346537B1/en not_active Expired - Lifetime
- 1997-12-05 CA CA002274485A patent/CA2274485C/en not_active Expired - Fee Related
- 1997-12-05 BR BR9713866-5A patent/BR9713866A/pt not_active Application Discontinuation
- 1997-12-05 AR ARP970105735A patent/AR008927A1/es active IP Right Grant
- 1997-12-05 HU HU0000587A patent/HU228680B1/hu not_active IP Right Cessation
- 1997-12-05 AU AU51369/98A patent/AU726451B2/en not_active Ceased
- 1997-12-05 KR KR1019990704614A patent/KR20000057242A/ko active Search and Examination
- 1997-12-05 RU RU99114776/14A patent/RU2197226C2/ru not_active IP Right Cessation
- 1997-12-05 ES ES97946111T patent/ES2286835T3/es not_active Expired - Lifetime
- 1997-12-05 DE DE69737936T patent/DE69737936T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE367150T1 (de) | 2007-08-15 |
TW426516B (en) | 2001-03-21 |
AR008927A1 (es) | 2000-02-23 |
CN1149979C (zh) | 2004-05-19 |
AU726451B2 (en) | 2000-11-09 |
RU2197226C2 (ru) | 2003-01-27 |
HUP0000587A1 (hu) | 2000-09-28 |
EP0943327B1 (en) | 2007-07-18 |
DE69737936T2 (de) | 2007-12-06 |
DE69737936D1 (de) | 2007-08-30 |
HU228680B1 (en) | 2013-05-28 |
AU5136998A (en) | 1998-06-29 |
CA2274485C (en) | 2008-02-05 |
ZA9710927B (en) | 1998-06-15 |
EP0943327A4 (en) | 2003-06-25 |
HUP0000587A3 (en) | 2001-12-28 |
ES2286835T3 (es) | 2007-12-01 |
CN1245424A (zh) | 2000-02-23 |
US6346537B1 (en) | 2002-02-12 |
JP4284706B2 (ja) | 2009-06-24 |
WO1998024418A1 (fr) | 1998-06-11 |
BR9713866A (pt) | 2000-03-14 |
EP0943327A1 (en) | 1999-09-22 |
CA2274485A1 (en) | 1998-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20000057242A (ko) | 의약 조성물 | |
KR100440553B1 (ko) | 서방성 제제 | |
KR100211085B1 (ko) | 활성성분으로 트리사이클릭 화합물을 함유하는 현탁조성물 및 그의 제조방법 | |
US6316473B1 (en) | Two surfactant-containing medicinal composition | |
KR20040002980A (ko) | 트리사이클릭 화합물을 포함하는 피부 질환의 예방 또는치료용 약제학적 조성물 | |
MXPA99005044A (en) | Medicinal composition | |
MXPA00009227A (en) | Sustained release preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
N231 | Notification of change of applicant | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050915 Effective date: 20061017 Free format text: TRIAL NUMBER: 2005101006186; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050915 Effective date: 20061017 |
|
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2006201010166; APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20061122 Effective date: 20071017 Free format text: TRIAL NUMBER: 2006201010166; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20061122 Effective date: 20071017 |